Languages

Digitalization, Sustainability, and Process Analytical Technology - Trends in Pharmaceutical and Bio-Pharmaceutical Industry 

Webinar Overview

Do you have sustainability goals? Where would you place your organization in the digitalization journey? Is process analytical technology being implemented or still something in the vision stage?

Often broken into economic, environmental, and social concepts, sustainability can be defined as the ability to maintain or support a process over time. Other definitions include the capacity of fulfilling the needs of current generation without compromising the needs of future generations, while ensuring a balance between economic growth, environmental care and social well-being. But what does this really mean for your organization and how can it be practically implemented? As an example, does digitalization aid sustainability or does it have an environmental impact by itself?

Join this webinar with Mark Henson, Head of Sustainable CMC at Takeda, Mark Milton, Associate Fellow at Takeda, Andrew Phillips, Head of Digitalization, Pharmaceutical Sciences, at AstraZeneca, Martin Gadsby, co-founder of Optimal Industrial Technologies and PAT expert and moderated by Anna Codina, Director of the Pharmaceutical Business Unit at Bruker BioSpin. They will discuss the correlation between digitalization, sustainability and process analytical technology and present practical examples of their implementation in pharma and biopharma.

Helium production and supply sustainability will also be discussed in the context of nuclear magnetic resonance (NMR) and solutions presented for helium recycling, as well as the latest results obtained from a cryogen-free benchtop spectrometer used as a smart detector for flow chemistry. Continuous-flow chemistry, compact and highly efficient by design, offers great advantages when combined with green chemistry principles and process analytical technology toward the development of a more sustainable chemistry and bioproduction.

Wednesday September 21, 2022

Key Learning Objectives

  • Key challenges in digital transformation
  • Gain insights on sustainability chemistry goals the pharmaceutical industry
  • Modern technologies that enable greener chemistry
  • Sustainability through the next generation of drugs
  • Economic significance and current challenges in the pharmaceutical industry
  • Digitalization and its impact from drug discovery to development
  • Insights into machine learning and artificial intelligence applications to Process Analytical Technology (PAT)

Who Should Attend

  • Pharmaceutical & Fine Chemists
  • Academic Chemistry Researchers
  • Process & Development Chemists
  • Drug Discovery and Development
  • Manufacturing in Pharmaceutical industry
  • Sustainability Directors

Speakers

Mark Henson

Head of Sustainability, Takeda

Mark Henson is a Senior Scientific Fellow and the Head of Sustainable CMC within Takeda Pharmaceutical Sciences R&D.  He has 21 years of R&D and commercial technical operations experience developing and applying innovative PAT, data modeling, and advanced processing capabilities for pharmaceuticals, embryology, and chemicals.  Mark now leads a strategic, cross-functional Sustainability & Innovation program for Takeda Pharm Sci R&D and chairs an associated Sustainability Board comprised of thought leaders from across the organization.

Mark holds a Ph.D. in Bio-Inorganic Chemistry from Stanford University, CA, U.S.A. 

Andy Phillips

Head of Digitization, AstraZeneca

Dr Andy Phillips has worked with AstraZeneca for 20 years – initially as an NMR spectroscopist & then leading a range of teams within Pharmaceutical Sciences across analytical chemistry & product development.  More recently Digital Transformation has become his focus leading both a project entitled ‘Digital Lab’ that has started a journey of investment across all AstraZeneca R&D labs & now as Head of Digitization within Pharmaceutical Sciences.

Martin Gadsby

Owner and Director, Optimal Industrial Automation

Martin graduated from the University of Bath in the late 1970’s, and after working through a few positions in industry, he became the European R&D Process and Process Automation Group Leader for Kraft Foods.  After a few years at Kraft, Martin decided to set up a process automation business with a colleague, Dave Richards, and Optimal was born. Optimal Industrial Automation was formed over 33 years ago, with Martin now being the Vice President of Optimal Industrial Technologies which was formed more recently as the products division and is the market leader in the field of Process Analytical Technology (PAT) with its PAT Knowledge Management product – synTQ.  Martin is intimately involved with progressing the evolution of synTQ and advising the Optimal development team on what he believes to be the optimum development direction.  Over the last few years, he has taken on the overall responsibility not only for the company but also for the sales and marketing of synTQ whilst remaining very active in ensuring that the development of synTQ continues unabated.  On the personal front, Martin is a bit of a ‘petrol head’ and enjoys flying aerobatics and racing cars.

Mark Milton

Associate Fellow, Takeda

Mark Milton obtained his PhD at the University of St. Andrews in Scotland in 1997 under the tutelage of Prof. Steve Homans using NMR to monitor the chemoenzymatic synthesis (and subsequent structure determination) of oligosaccharides . He then went on to be a Postdoctoral Fellow at the University of Alberta and the University of Pennsylvania. He then made the jump to industry and took a research position at Wyeth, Pearl River, NY before moving to Millennium Pharmaceuticals (later Takeda Pharmaceuticals) in 2004. In 2011 with scientists from MIT and Amgen, he co-founded NewNMR (www.newnmr.org), a Boston based NMR scientific discussion group, and has been its President since its inception. His current research focus is developing the potential of small form factor, mobile versions of NMR technologies to bring the power of NMR direct to the chemists fume hood.

Dr. Anna Codina

Director Pharmaceutical Business Unit, Bruker BioSpin

Anna has a degree in Chemistry and a PhD in Protein NMR from the University of Barcelona, Spain. During this time she did several industrial placements at pharmaceutical industries (Pharmhispania, Spain, and Genentech, SF, USA) and she worked for the NMR service of the University. She then moved to Cambridge, UK, to do a post-doc in protein NMR at the MRC Laboratory of Molecular Biology.

After her post-doc she worked in the Analytical R&D department of Pfizer, UK, for 8 years, becoming proficient in low level impurity structure elucidation, reaction monitoring, qNMR and the preparation of regulatory documentation.

She joined Bruker in 2011 as Material Characterisation Laboratory Manager. Since then her role has evolved. She started looking after the pharmaceutical market in 2015 as Product Portfolio Manager. Anna and team launched several products: InsightMR, InsightXpress and InsighCell for process understanding and monitoring; Fragment Based Screening analysis tools, PotencyMR for potency determination of drugs by qNMR; the minispec Form Check for solid form quantification and NMR Instrument Qualification packages to facilitate compliance. She is now director of the pharmaceutical business Unit at Bruker BioSpin.